AU2002215384A1 - Hydroxyapatite-targeting poly(ethylene glycol) and related polymers - Google Patents

Hydroxyapatite-targeting poly(ethylene glycol) and related polymers

Info

Publication number
AU2002215384A1
AU2002215384A1 AU2002215384A AU1538402A AU2002215384A1 AU 2002215384 A1 AU2002215384 A1 AU 2002215384A1 AU 2002215384 A AU2002215384 A AU 2002215384A AU 1538402 A AU1538402 A AU 1538402A AU 2002215384 A1 AU2002215384 A1 AU 2002215384A1
Authority
AU
Australia
Prior art keywords
hydroxyapatite
ethylene glycol
related polymers
targeting poly
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002215384A
Inventor
Antoni Kozlowski
Michael James Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics AL Corp
Original Assignee
Shearwater Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shearwater Corp filed Critical Shearwater Corp
Publication of AU2002215384A1 publication Critical patent/AU2002215384A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
AU2002215384A 2000-11-14 2001-10-18 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers Abandoned AU2002215384A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/712,536 US6436386B1 (en) 2000-11-14 2000-11-14 Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US09/712,536 2000-11-14
PCT/US2001/032566 WO2002040058A2 (en) 2000-11-14 2001-10-18 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers

Publications (1)

Publication Number Publication Date
AU2002215384A1 true AU2002215384A1 (en) 2002-05-27

Family

ID=24862528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002215384A Abandoned AU2002215384A1 (en) 2000-11-14 2001-10-18 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers

Country Status (5)

Country Link
US (1) US6436386B1 (en)
EP (1) EP1337274A2 (en)
JP (2) JP2004522712A (en)
AU (1) AU2002215384A1 (en)
WO (1) WO2002040058A2 (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100729977B1 (en) * 1999-12-22 2007-06-20 넥타르 테라퓨틱스 에이엘, 코포레이션 Method for the preparation of 1-benzotriazolyl carbonate esters of polyethylene glycol
JP2003523544A (en) * 2000-02-17 2003-08-05 レックスマーク・インターナショナル・インコーポレーテツド Composition containing fine particles for supporting biologically active substance thereon or having the same supported thereon and method for preparing these
US7829074B2 (en) * 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US7311892B2 (en) * 2001-10-26 2007-12-25 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
WO2004024889A2 (en) * 2002-09-16 2004-03-25 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
WO2004089345A1 (en) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals Inc. Bone targeting of biodegradable drug-containing nanoparticles
EP1615639A2 (en) * 2003-04-03 2006-01-18 Semafore Pharmaceuticals, Inc. Targeted bone marrow protection agents
JP4463274B2 (en) * 2003-06-27 2010-05-19 明 小谷 Bisphosphonate complex
JP4604238B2 (en) * 2003-09-19 2011-01-05 独立行政法人産業技術総合研究所 Polymer composite containing calcium phosphate and physiologically active substance, method for producing the same, and medical material using the same
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US20070265200A1 (en) * 2004-03-17 2007-11-15 Eli Lilly And Company Glycol Linked Fgf-21 Compounds
ES2641570T3 (en) 2004-03-31 2017-11-10 University Of Utah Research Foundation Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
HUE039448T2 (en) * 2004-04-21 2018-12-28 Alexion Pharma Inc Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
AU2005265163B2 (en) 2004-06-18 2009-10-01 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
AU2005275062A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
CN101087875B (en) 2004-12-22 2012-08-22 Ambrx公司 Compositions of aminoacyl-tRNA synthetase and uses thereof
BRPI0519430A2 (en) 2004-12-22 2009-02-10 Ambrx Inc modified human growth hormone
BRPI0518661A2 (en) 2004-12-22 2008-12-02 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US8183340B2 (en) 2005-05-13 2012-05-22 Eli Lilly And Company GLP-1 pegylated compounds
KR20080026135A (en) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 Improved human interferon molecules and their uses
EP2339014B1 (en) 2005-11-16 2015-05-27 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
RU2457854C2 (en) * 2005-12-30 2012-08-10 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед Prolonged release of neuregulin for improvement in cardiac function
US20100040668A1 (en) * 2006-01-12 2010-02-18 Rutgers, The State University Of New Jersey Biomimetic Hydroxyapatite Composite Materials and Methods for the Preparation Thereof
US8287914B2 (en) * 2006-01-12 2012-10-16 Rutgers, The State University Of New Jersey Biomimetic hydroxyapatite synthesis
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
WO2008005509A2 (en) * 2006-07-06 2008-01-10 Massachusetts Institute Of Technology Methods and compositions for altering biological surfaces
WO2008017029A2 (en) * 2006-08-02 2008-02-07 Board Of Regents Of The University Of Nebraska Drug carriers, their synthesis, and methods of use thereof
MX2009002526A (en) 2006-09-08 2009-04-16 Ambrx Inc Suppressor trna transcription in vertebrate cells.
KR20090060294A (en) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 Modified human plasma polypeptide or fc scaffolds and their uses
KR20090051227A (en) 2006-09-08 2009-05-21 암브룩스, 인코포레이티드 Hybrid suppressor trna for vertebrate cells
US7999085B2 (en) * 2007-01-09 2011-08-16 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008088983A1 (en) 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
CN101265331B (en) * 2007-03-12 2010-10-13 中国科学院化学研究所 PEG modifying PHPMA material and preparation method thereof
BRPI0809583B1 (en) 2007-03-30 2022-02-22 Ambrx, Inc Modified fgf-21 polypeptide, composition comprising the same, method for producing said fgf-21 polypeptide, and cell comprising a polynucleotide
BRPI0810622A2 (en) 2007-05-02 2020-10-13 Ambrx, Inc. modified interferon beta polypeptides and their uses
AU2008258285B2 (en) 2007-06-08 2013-03-21 Queensland University Of Technology Wound repair composition and method
EP2177525A1 (en) 2007-07-06 2010-04-21 TMRC Co., Ltd. Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound
KR101165455B1 (en) * 2007-09-10 2012-07-12 한스바이오메드 주식회사 Calcium phosphate microspheres drug delivery system and process for preparing the same
EP2214716B1 (en) * 2007-10-23 2021-11-17 Nektar Therapeutics Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
JP2011010549A (en) * 2007-10-29 2011-01-20 Univ Of Tokyo Organic-inorganic hybrid nano particle composed of nucleic acid conjugate having polyethylene glycol bound thereto and calcium phosphate
CN101918026B (en) 2007-11-20 2016-03-02 Ambrx公司 Modified insulin polypeptides and its purposes
JP5328672B2 (en) * 2007-12-10 2013-10-30 コスメディ製薬株式会社 Transdermal absorption preparation
JP2010018772A (en) * 2008-01-25 2010-01-28 Ebara Corp Peg-modified hydroxyapatite, pharmaceutical using the same as base material and production process thereof
JP5702150B2 (en) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. Modified leptin polypeptides and their use
US11033631B2 (en) 2008-06-09 2021-06-15 Nektar Therapeutics Methods of treating CYP2D6 alternative metabolizers
PL2318837T4 (en) 2008-07-11 2016-10-31 Enhanced immunoassay sensor
UA103774C2 (en) 2008-07-23 2013-11-25 Амбркс, Інк. Modified bovine g-csf polypeptides and their uses
CN107022020A (en) 2008-09-26 2017-08-08 Ambrx公司 The animal erythropoietin polypeptides and its purposes of modification
MX343802B (en) 2008-09-26 2016-11-23 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines.
CA2778678A1 (en) 2009-10-30 2011-05-05 Cns Therapeutics, Inc. Improved neurturin molecules
EA201290541A1 (en) 2009-12-21 2013-05-30 Амбркс, Инк. MODIFIED BULL SOMATOTROPINE POLYPEPTIDES AND THEIR APPLICATION
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
EP2563380B1 (en) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
JP6294074B2 (en) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of isoleucyl-tRNA synthetase
AU2011248489B2 (en) 2010-04-28 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
JP5991963B2 (en) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of valyl tRNA synthetase
CA2797865A1 (en) 2010-04-30 2011-11-03 Alexion Pharma International Sarl Methods, compositions, and kits for the treatment of matrix mineralization disorders
JP6008841B2 (en) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of methionyl tRNA synthetase
CN103096912A (en) 2010-05-03 2013-05-08 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
EP2566515B1 (en) 2010-05-03 2017-08-02 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103119055A (en) 2010-05-17 2013-05-22 塞比克斯公司 Pegylated C-Peptide
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
CN103118694B (en) 2010-06-01 2016-08-03 Atyr医药公司 The discovery for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of lysyl-tRNA synzyme
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MA34521B1 (en) 2010-08-17 2013-09-02 Ambrx Inc MODIFIED RELAXINE POLYPEPTIDES AND USES THEREOF
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
CN104220086A (en) 2011-11-17 2014-12-17 塞比克斯股份公司 PEGylated C-peptide
EP2814514B1 (en) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN104448296B (en) * 2013-12-02 2018-01-05 北京键凯科技股份有限公司 alkynyl multi-arm polyethylene glycol derivative
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CN104086763A (en) * 2014-04-03 2014-10-08 西南交通大学 Amino-containing diphosphonate modified Brij compound used as surfactant, and preparation method thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CN114805533A (en) 2014-10-24 2022-07-29 百时美施贵宝公司 Modified FGF-21 polypeptides and uses thereof
JP6787894B2 (en) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド Treatment of seizures with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
KR102644116B1 (en) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 Preparation of alkaline phosphatase
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
MX2018011833A (en) 2016-04-01 2019-02-13 Alexion Pharma Inc Treating muscle weakness with alkaline phosphatases.
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3492166A4 (en) * 2016-08-01 2020-03-11 Kaneka Corporation Adsorbent for calciprotein particles, adsorption removal system, and method of using same
EP3496750A2 (en) 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
TW201837051A (en) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
EP3688007A1 (en) 2017-09-27 2020-08-05 The University of York Bioconjugation of polypeptides
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
KR102167755B1 (en) 2018-05-23 2020-10-19 주식회사 큐어바이오 Fragmented GRS polypeptide, mutants thereof and use thereof
CN108786713B (en) * 2018-06-08 2021-04-27 南京师范大学 Amphiphilic adsorption type sulfhydryl modified nano hydroxyapatite adsorbent and preparation method and application thereof
PT3849614T (en) 2018-09-11 2024-02-28 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
JP2022512746A (en) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド Interleukin-10 polypeptide complex, its dimer, and their use
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2021018922A1 (en) * 2019-07-30 2021-02-04 Gatt Technologies B.V. Polyoxazoline copolymer comprising calcium binding groups
IL294659A (en) 2020-01-14 2022-09-01 Synthekine Inc Biased il2 muteins methods and compositions
JP2023517595A (en) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド Interleukin-2 polypeptide conjugates and methods of use thereof
KR20230073200A (en) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 Antibody-TLR agonist conjugates, methods and uses thereof
JP2024512775A (en) 2021-04-03 2024-03-19 アンブルックス，インコーポレイテッド Anti-HER2 antibody drug conjugate and its use
CN115043908B (en) * 2022-06-10 2023-10-13 浙江大学 Hydroxyapatite targeting peptide and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8310438D0 (en) 1983-04-18 1983-05-25 Amersham Int Plc Bone-seeking complexes of technetium-99m
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
ES8802468A1 (en) * 1985-05-02 1988-07-16 Research Corp Bone targeted inhibitors of carbonic anhydrase.
JPH02268190A (en) 1989-04-07 1990-11-01 Fujisawa Pharmaceut Co Ltd Conjugate from medical compound and diphosphonic acid derivative
JP2517760B2 (en) * 1989-05-11 1996-07-24 新技術事業団 Water-soluble polymerized pharmaceutical preparation
FR2676058B1 (en) 1991-04-30 1994-02-25 Hoechst Lab GLYCOSYLATED PRODUCTS, THEIR PREPARATION PROCESS AND THEIR USE IN THE TREATMENT OF CANCERS.
AU662155B2 (en) * 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
US5413992A (en) 1992-07-31 1995-05-09 The Scripps Research Institute Daunomycin derivative with reduced cytotoxicity toward normal cells
DE4236237A1 (en) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, their preparation and use as medicines
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
GB9613722D0 (en) 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds
US5830986A (en) * 1996-10-28 1998-11-03 Massachusetts Institute Of Technology Methods for the synthesis of functionalizable poly(ethylene oxide) star macromolecules
CN1254293A (en) * 1997-02-13 2000-05-24 骨疗国际公司 Targeted therapeutic delivery of vitamin D compounds
KR100729977B1 (en) * 1999-12-22 2007-06-20 넥타르 테라퓨틱스 에이엘, 코포레이션 Method for the preparation of 1-benzotriazolyl carbonate esters of polyethylene glycol
AU2001262952A1 (en) * 2000-04-27 2001-11-07 Wm. Marsh Rice University Fullerene-based drugs targeted to bone
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives

Also Published As

Publication number Publication date
JP2004522712A (en) 2004-07-29
JP2009197023A (en) 2009-09-03
WO2002040058A3 (en) 2003-01-03
US6436386B1 (en) 2002-08-20
EP1337274A2 (en) 2003-08-27
WO2002040058A2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU2002215384A1 (en) Hydroxyapatite-targeting poly(ethylene glycol) and related polymers
AU6221801A (en) End-capped polyfluorenes, films and devices based thereon
AU2001276597A1 (en) Biodegradable polymeric blend
AU2002340793A1 (en) Molecular memory device
AU6509000A (en) High melt swell polymer
AU6009001A (en) Self-lubricating polymers
AUPR259301A0 (en) Polymers having co-continuous architecture
AU2587299A (en) Alkylene oxide polymer compositions
AU2001270819A1 (en) Polymer electrolyte
AUPR216100A0 (en) Porous polymers
AU2001286657A1 (en) Propylene polymer composition
AU6366700A (en) Polyphosphazene polymers
AU2001259395A1 (en) Hybrid end-capped reactive silicone polymers
AU2001235773A1 (en) Electro-luminiscent polymers, their preparation and uses
AU2002210913A1 (en) Hydrogenated polymer
AU2001276749A1 (en) Polymer composition
AU2001285810A1 (en) High functional polymers
AU2001269961A1 (en) Improved polymers and polymerization processes
AU2002220837A1 (en) Alkylene oxide-lactone copolymers
AU2001249871A1 (en) Ether-amine based polymerization catalysts, compositions and processes using same
AUPR218000A0 (en) Polymer gels and their preparation
AUPQ901700A0 (en) Molecular markers
AU2001284503A1 (en) Enzyme-mimicking polymers
AU2001285901A1 (en) High functional polymers
AU2001283928A1 (en) Polymer chip